Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism

Baht, Gurpreet S.; Bareja, Akshay; Lee, David E.; Rao, Rajesh R.; Ron, Huang; Huebner, Janet L.; Bartlett, David B.; Hart, Corey R.; Gibson, Jason; Lanza, Ian R.; Kraus, Virginia B.; Gregory, Simon; Spiegelman, Bruce M.; White, James P.

doi:10.1038/s42255-020-0184-y

Cited by 110 publications

(108 citation statements)

References 45 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Meteorin-like (METRNL) protein is a newly identified myokine that acts to regulate energy expenditure and inflammation in adipose tissue [ [21] , [22] , [23] ]. Besides, METRNL is reported to be abundantly expressed in the heart and plays critical roles during the pathogenesis of cardiovascular diseases [ 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway

et al. 2020

View full text Add to dashboard Cite

Meteorin-like (METRNL) protein is a newly identified myokine that functions to modulate energy expenditure and inflammation in adipose tissue. Herein, we aim to investigate the potential role and molecular basis of METRNL in doxorubicin (DOX)-induced cardiotoxicity. METRNL was found to be abundantly expressed in cardiac muscle under physiological conditions that was decreased upon DOX exposure. Cardiac-specific overexpression of METRNL by adeno-associated virus serotype 9 markedly improved oxidative stress, apoptosis, cardiac dysfunction and survival status in DOX-treated mice. Conversely, knocking down endogenous METRNL by an intramyocardial injection of adenovirus exacerbated DOX-induced cardiotoxicity and death. Meanwhile, METRNL overexpression attenuated, while METRNL silence promoted oxidative damage and apoptosis in DOX-treated H9C2 cells. Systemic METRNL depletion by a neutralizing antibody aggravated DOX-related cardiac injury and dysfunction in vivo, which were notably alleviated by METRNL overexpression within the cardiomyocytes. Besides, we detected robust METRNL secretion from isolated rodent hearts and cardiomyocytes, but to a less extent in those with DOX treatment. And the beneficial effects of METRNL in H9C2 cells disappeared after the incubation with a METRNL neutralizing antibody. Mechanistically, METRNL activated SIRT1 via the cAMP/PKA pathway, and its antioxidant and antiapoptotic capacities were blocked by SIRT1 deficiency. More importantly, METRNL did not affect the tumor-killing action of DOX in 4T1 breast cancer cells and tumor-bearing mice. Collectively, cardiac-derived METRNL activates SIRT1 via cAMP/PKA signaling axis in an autocrine manner, which ultimately improves DOX-elicited oxidative stress, apoptosis and cardiac dysfunction. Targeting METRNL may provide a novel therapeutic strategy for the prevention of DOX-associated cardiotoxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The adipokine/myokine meteorin-like (METNRL) was recently identified as a novel, important regulator of muscle repair and adipose tissue function [15,16]. METNRL is induced by physical exercise and exposure to cold temperatures.…”

Section: Introductionmentioning

confidence: 99%

Hepatic Meteorin-like and Krüppel-like Factor 3 are Associated with Weight Loss and Liver Injury

Grander

Grabherr

Enrich

et al. 2021

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Objective Laparoscopic adjustable gastric banding (LAGB) was found to be effective in reducing body weight and improving insulin resistance in patients with obesity and non-alcoholic fatty liver disease (NAFLD). The adipokine/myokine meteorin-like (METNRL) is an important regulator of whole-body energy expenditure. Krüppel-like factor 3 (KLF3), a regulator of METRNL expression in eosinophils, inhibits the beiging of adipose tissue in mice and therefore regulates adipose tissue development. Methods Thirty-three obese patients undergoing LAGB were included in the study. The hepatic and adipose tissue expression of METNRL and KLF3 was determined before (t0) and 6 months after (t6) LABG. The human liver cancer cell line (HepG2) was stimulated with cytokines and fatty acids and METNRL and KLF3 expressions were analyzed. Results LAGB-associated weight loss was correlated with decreased hepatic METNRL expression. The expression of METNRL and KLF3 in hepatic-and adipose tissues correlated before and after LAGB. Individuals with augmented LAGB-induced weight loss (>20 kg) showed lower hepatic METNRL and KLF3 expression before and after LAGB than patients with <20 kg weight loss. METNRL and KLF3 levels were higher in patients with higher NAFLD activity scores. HepG2 stimulation with interleukin-1β, tumor necrosis factor-α, palmitic acid but not interleukin-6, oleic acid, or lipopolysaccharide, induced the expression of one or both investigated adipokines. Conclusions The novel description of METRNL and KLF3 as hepatokines could pave the way to target their production and/or signaling in obesity, NAFLD, and related disorders. Both proteins may act as possible biomarkers to estimate weight loss after bariatric surgery.

show abstract

“…An intraperitoneal injection of recombinant Metrnl improved glucose tolerance in mice with high-fat diet-induced obesity and T2DM. Perhaps Meteorin-like is a promising therapeutic candidate for obesity, T2DM and related CMDs [ 39 , 40 , 41 ].…”

Section: Metabotrophic Factors As Therapeutic Targets In Drug Discoverymentioning

confidence: 99%

Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy

Fröhlich

Chaldakov

Vinciguerra

2021

IJMS

View full text Add to dashboard Cite

Studies over the past 30 years have revealed that adipose tissue is the major endocrine and paracrine organ of the human body. Arguably, adiopobiology has taken its reasonable place in studying obesity and related cardiometabolic diseases (CMDs), including Alzheimer’s disease (AD), which is viewed herein as a neurometabolic disorder. The pathogenesis and therapy of these diseases are multiplex at basic, clinical and translational levels. Our present goal is to describe new developments in cardiometabolic and neurometabolic adipobiology. Accordingly, we focus on adipose- and/or skeletal muscle-derived signaling proteins (adipsin, adiponectin, nerve growth factor, brain-derived neuroptrophic factor, neurotrophin-3, irisin, sirtuins, Klotho, neprilysin, follistatin-like protein-1, meteorin-like (metrnl), as well as growth differentiation factor 11) as examples of metabotrophic factors (MTFs) implicated in the pathogenesis and therapy of obesity and related CMDs. We argue that these pathologies are MTF-deficient diseases. In 1993 the “vascular hypothesis of AD” was published and in the present review we propose the “vasculometabolic hypothesis of AD.” We discuss how MTFs could bridge CMDs and neurodegenerative diseases, such as AD. Greater insights on how to manage the MTF network would provide benefits to the quality of human life.

show abstract

Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism

Cited by 110 publications

References 45 publications

Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway

Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway

Hepatic Meteorin-like and Krüppel-like Factor 3 are Associated with Weight Loss and Liver Injury

Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy

Contact Info

Product

Resources

About